You are currently browsing the archives for 28 April 2017.
Displaying 1 entry.

A leading RNAi therapeutics firm

Alnylam to provide data on RNAi therapeutics for fibrotic diseases at The Liver Meeting Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics firm, announced today it will present several poster presentations at the 61st Annual Achieving of the American Association for the analysis of Liver Illnesses becoming held in Boston, Mass from October 29 – November 2, 2010. At the conference, new research linked to the business’s pre-clinical and scientific pipeline attempts will be shown, including new data displaying effective delivery of RNAi therapeutics to hepatic stellate cells .